AlphaYou
Overview
No source-backed view yet. This page is available for price, fundamentals, and future receipts as coverage warms.
Key stats
Aug 20- 52-wk high
- $161.38
- 52-wk low
- $49.13
- Prev close
- $97.14
- Mkt cap
- $2.16B
- P/B
- 10.0x
- Profit margin
- +0.0%
Smart money
Earnings
Earnings came in 31.0% below what analysts expected.
Financials
What it sold, what it cost, what was left.
Sep 2025Dec 2025Mar 2026Jun 2026
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $0 | $0 | $0 | $0 |
| What it spent | ||||
| Research and development | $6.5M | $7.1M | $9.3M | $12.5M |
| Sales and admin | $3.6M | $4.2M | $5.5M | $8.9M |
| Total operating expenses | $10.2M | $11.3M | $14.9M | $21.4M |
| What was left | ||||
| Operating profit | -$10.2M | -$11.3M | -$14.9M | -$21.4M |
| Interest on debt | $1.5M | $1.7M | $2.0M | $2.3M |
| Profit before tax | -$11.3M | -$12.7M | -$15.8M | -$21.9M |
| Net profit | -$11.3M | -$12.7M | -$15.8M | -$21.9M |
| EBITDA | $342.0K | -$11.0M | -$17.8M | -$21.6M |
Technicals
Price structure
No data yet
Technicals sync when verified market data is available. No sample data is shown.
News
What the news says
5 articles · 7 days
Coverage is bullish
Tone of tracked coverage
Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands
BullishAug 17Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
Leans bullishAug 9Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Consensus Rating of "Buy" from Analysts
NeutralAug 7
